DK1107996T3 - Humane anti-faktor IX/IXa-antistoffer - Google Patents

Humane anti-faktor IX/IXa-antistoffer

Info

Publication number
DK1107996T3
DK1107996T3 DK99943928T DK99943928T DK1107996T3 DK 1107996 T3 DK1107996 T3 DK 1107996T3 DK 99943928 T DK99943928 T DK 99943928T DK 99943928 T DK99943928 T DK 99943928T DK 1107996 T3 DK1107996 T3 DK 1107996T3
Authority
DK
Denmark
Prior art keywords
factor
ixa
fix
human anti
inhibiting
Prior art date
Application number
DK99943928T
Other languages
English (en)
Inventor
Camellia W Adams
Brigitte Devaux
Dan L Eaton
Philip E Hass
J Kevin Judice
Daniel Kirchhofer
Shelley Suggett
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1107996T3 publication Critical patent/DK1107996T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99943928T 1998-08-28 1999-08-26 Humane anti-faktor IX/IXa-antistoffer DK1107996T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03
PCT/US1999/019453 WO2000012562A1 (en) 1998-08-28 1999-08-26 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number Publication Date
DK1107996T3 true DK1107996T3 (da) 2002-09-16

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943928T DK1107996T3 (da) 1998-08-28 1999-08-26 Humane anti-faktor IX/IXa-antistoffer

Country Status (15)

Country Link
US (3) US6624295B1 (da)
EP (1) EP1107996B1 (da)
JP (1) JP4638035B2 (da)
CN (1) CN1183160C (da)
AT (1) ATE217889T1 (da)
AU (1) AU766551C (da)
BR (1) BR9913435A (da)
CA (1) CA2341276C (da)
DE (1) DE69901569T2 (da)
DK (1) DK1107996T3 (da)
ES (1) ES2177316T3 (da)
IL (1) IL140917A0 (da)
NZ (1) NZ509430A (da)
PT (1) PT1107996E (da)
WO (1) WO2000012562A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
ATE493503T1 (de) * 2006-09-22 2011-01-15 Wacker Chemie Ag Verfahren zur fermentativen herstellung von proteinen
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
DK2552948T3 (da) 2010-03-30 2016-10-17 Octapharma Ag Fremgangsmåde til rensning af vækstfaktorprotein G-CSF
EP2553095B1 (en) * 2010-03-30 2016-10-12 Octapharma AG A process for purifying vitamin K dependent proteins such as coagulation factor IX
CA2795325A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
WO2012161226A1 (ja) * 2011-05-23 2012-11-29 積水メディカル株式会社 Pivka-ii測定試薬における非特異反応の抑制方法
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
WO1991016353A1 (en) 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
CZ292061B6 (cs) 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
AU5692399A (en) 2000-03-21
NZ509430A (en) 2002-04-26
AU766551C (en) 2005-02-17
EP1107996B1 (en) 2002-05-22
AU766551B2 (en) 2003-10-16
EP1107996A1 (en) 2001-06-20
US20060088534A1 (en) 2006-04-27
DE69901569D1 (de) 2002-06-27
US7049411B2 (en) 2006-05-23
US20060193851A1 (en) 2006-08-31
WO2000012562A1 (en) 2000-03-09
JP4638035B2 (ja) 2011-02-23
PT1107996E (pt) 2002-10-31
DE69901569T2 (de) 2002-12-19
CN1183160C (zh) 2005-01-05
US6624295B1 (en) 2003-09-23
ATE217889T1 (de) 2002-06-15
US7354585B2 (en) 2008-04-08
IL140917A0 (en) 2002-02-10
BR9913435A (pt) 2001-09-25
ES2177316T3 (es) 2002-12-01
CA2341276A1 (en) 2000-03-09
JP2002523081A (ja) 2002-07-30
CN1317015A (zh) 2001-10-10
CA2341276C (en) 2005-10-11

Similar Documents

Publication Publication Date Title
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
MEP8209A (en) Modified factor viii
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
EP1474121A4 (en) SMALL MOLECULAR ANTAGONISTS OF PROTEINS OF THE BCL2 FAMILY
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
TR200001954T2 (tr) Faktör XA'nın önleyicileri olarak indol türevleri.
DE50010115D1 (de) Zusammensetzung und verfahren zur entkeimung von luft
DK0842934T3 (da) 5-HT1F agonister
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
EP1064308A4 (en) METHODS FOR IDENTIFYING INDUCERS AND INHIBITORS OF PROTEOLYTIC ANTIBODIES, AND COMPOSITIONS AND USES THEREOF
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
BRPI0415285A (pt) derivados de aminoalcanol